Safety and efficacy of re-treatment with [¹⁷⁷Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.

ABSTRACT:

Aim

Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initial response to [¹⁷⁷Lu]Lu-DOTA-Octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) are amenable to re-treatment (R-PRRT) upon progression. We assessed the safety and efficacy of R-PRRT in patients with progressive metastatic GEP NET.

Materials and methods

A retrospective analysis, approved by institutional ethics board, was performed in patients with GEP NET who received R-PRRT for either symptomatically or radiologically progressive disease. Safety was assessed by renal and haematological parameters at 3 months post R-PRRT (CTCAE v5.0). Molecular imaging response was evaluated on [⁶⁸Ga]Ga-DOTA-Octreotate

SUBMITTER: Kashyap R 

PROVIDER: S-EPMC12316713 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature